202 related articles for article (PubMed ID: 25100867)
1. Hepatitis B virus sub-genotype A1 infection is characterized by high replication levels and rapid emergence of drug resistance in HIV-positive adults receiving first-line antiretroviral therapy in Malawi.
Aoudjane S; Chaponda M; González Del Castillo AA; O'Connor J; Noguera M; Beloukas A; Hopkins M; Khoo S; van Oosterhout JJ; Geretti AM
Clin Infect Dis; 2014 Dec; 59(11):1618-26. PubMed ID: 25100867
[TBL] [Abstract][Full Text] [Related]
2. Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of mother-to-infant transmission in Malawi.
Galluzzo C; Liotta G; Andreotti M; Luhanga R; Jere H; Mancinelli S; Maulidi M; Sagno JB; Pirillo M; Erba F; Amici R; Ceffa S; Marazzi MC; Vella S; Palombi L; Giuliano M
J Med Virol; 2012 Oct; 84(10):1553-7. PubMed ID: 22930502
[TBL] [Abstract][Full Text] [Related]
3. HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.
Hamers RL; Zaaijer HL; Wallis CL; Siwale M; Ive P; Botes ME; Sigaloff KC; Hoepelman AI; Stevens WS; Rinke de Wit TF;
J Acquir Immune Defic Syndr; 2013 Oct; 64(2):174-82. PubMed ID: 23892239
[TBL] [Abstract][Full Text] [Related]
4. Impact of Lamivudine-Based Antiretroviral Treatment on Hepatitis B Viremia in HIV-Coinfected South Africans.
Lukhwareni A; Gededzha MP; Amponsah-Dacosta E; Blackard JT; Burnett RJ; Selabe SG; Kyaw T; Mphahlele MJ
Viruses; 2020 Jun; 12(6):. PubMed ID: 32545313
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and molecular characterization of hepatitis B virus infection in HIV-infected children in Senegal.
Toyé RM; Lô G; Diop-Ndiaye H; Cissé AM; Ndiaye AJS; Kébé-Fall K; Dramé A; Cohen D; Pujol FH; Mboup S; Boye CS; Chemin I; Laborde-Balen G; Taverne B; Touré-Kane C
Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101502. PubMed ID: 32828748
[TBL] [Abstract][Full Text] [Related]
6. HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya.
Kim HN; Scott J; Cent A; Cook L; Morrow RA; Richardson B; Tapia K; Jerome KR; Lule G; John-Stewart G; Chung MH
J Viral Hepat; 2011 Oct; 18(10):e447-52. PubMed ID: 21914062
[TBL] [Abstract][Full Text] [Related]
7. Long-term hepatitis B virus (HBV) response to lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand.
Khamduang W; Gaudy-Graffin C; Ngo-Giang-Huong N; Jourdain G; Moreau A; Luekamlung N; Halue G; Buranawanitchakorn Y; Kunkongkapan S; Buranabanjasatean S; Lallemant M; Sirirungsi W; Goudeau A;
PLoS One; 2012; 7(7):e42184. PubMed ID: 22860080
[TBL] [Abstract][Full Text] [Related]
8. Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Côte d'Ivoire.
Boyd A; Moh R; Gabillard D; le Carrou J; Danel C; Anglaret X; Eholié SP; Maylin S; Delaugerre C; Zoulim F; Girard PM; Lacombe K;
Antivir Ther; 2015; 20(6):643-54. PubMed ID: 25852125
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B viremia in HIV-coinfected individuals under antiretroviral therapy.
Weissmann L; Picone CM; Gouvêa MSG; Ferreira PRA; Viana MSVB; Pinho JRR; Cassenote AJF; Segurado AC
Braz J Infect Dis; 2019; 23(6):441-450. PubMed ID: 31715124
[TBL] [Abstract][Full Text] [Related]
10. Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy.
Hafkin JS; Osborn MK; Localio AR; Amorosa VK; Kostman JR; Stern JJ; De La Torre P; Mounzer K; Frank I; Gross R; Chang KM; Lo Re V
J Viral Hepat; 2014 Apr; 21(4):288-96. PubMed ID: 24597697
[TBL] [Abstract][Full Text] [Related]
11. New Insights on Long-Term Hepatitis B Virus Responses in HIV-Hepatitis B virus Co-infected Patients: Implications for Antiretroviral Management in Hepatitis B virus-Endemic Settings.
Dunn D; Price H; Vudriko T; Kityo C; Musoro G; Hakim J; Gilks C; Kaleebu P; Pillay D; Gilson R;
J Acquir Immune Defic Syndr; 2021 Jan; 86(1):98-103. PubMed ID: 33306565
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B Infection, Viral Load and Resistance in HIV-Infected Patients in Mozambique and Zambia.
Wandeler G; Musukuma K; Zürcher S; Vinikoor MJ; Llenas-García J; Aly MM; Mulenga L; Chi BH; Ehmer J; Hobbins MA; Bolton-Moore C; Hoffmann CJ; Egger M;
PLoS One; 2016; 11(3):e0152043. PubMed ID: 27032097
[TBL] [Abstract][Full Text] [Related]
13. Differential clinical and virologic impact of hepatitis B virus genotypes B and C on HIV-coinfected patients receiving lamivudine-containing highly active antiretroviral therapy.
Sheng WH; Hung CC; Chang SY; Liu CJ; Chen MY; Hsieh SM; Kao JH; Chen PJ; Chang SC
Clin Infect Dis; 2012 Feb; 54(4):548-55. PubMed ID: 22156858
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B virus drug resistance in HIV-1-infected patients taking lamivudine-containing antiretroviral therapy.
Wongprasit P; Manosuthi W; Kiertiburanakul S; Sungkanuparph S
AIDS Patient Care STDS; 2010 Apr; 24(4):205-9. PubMed ID: 20377434
[TBL] [Abstract][Full Text] [Related]
15. Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon.
Mbougua JB; Laurent C; Kouanfack C; Bourgeois A; Ciaffi L; Calmy A; Gwet H; Koulla-Shiro S; Ducos J; Mpoudi-Ngolé E; Molinari N; Delaporte E
BMC Public Health; 2010 Mar; 10():105. PubMed ID: 20193053
[TBL] [Abstract][Full Text] [Related]
16. Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in Ghana.
Stockdale AJ; Phillips RO; Beloukas A; Appiah LT; Chadwick D; Bhagani S; Bonnett L; Sarfo FS; Dusheiko G; Geretti AM;
Clin Infect Dis; 2015 Sep; 61(6):883-91. PubMed ID: 26021992
[TBL] [Abstract][Full Text] [Related]
17. High Prevalence of Hepatitis B Virus Drug Resistance Mutations to Lamivudine among People with HIV/HBV Coinfection in Rural and Peri-Urban Communities in Botswana.
Phinius BB; Anderson M; Gobe I; Mokomane M; Choga WT; Phakedi B; Ratsoma T; Mpebe G; Makhema J; Shapiro R; Lockman S; Musonda R; Moyo S; Gaseitsiwe S
Viruses; 2024 Apr; 16(4):. PubMed ID: 38675933
[TBL] [Abstract][Full Text] [Related]
18. Lamivudine-resistant HBV infection in HIV-positive patients receiving antiretroviral therapy in a public routine clinic in Cameroon.
Kouanfack C; Aghokeng AF; Mondain AM; Bourgeois A; Kenfack A; Mpoudi-Ngolé E; Ducos J; Delaporte E; Laurent C
Antivir Ther; 2012; 17(2):321-6. PubMed ID: 22290198
[TBL] [Abstract][Full Text] [Related]
19. High incidence of lamivudine-resistance-associated vaccine-escape HBV mutants among HIV-coinfected patients on prolonged antiretroviral therapy.
Pal A; Sarkar N; Saha D; Guha SK; Saha B; Chakrabarti S; Chakravarty R
Antivir Ther; 2015; 20(5):545-54. PubMed ID: 25654813
[TBL] [Abstract][Full Text] [Related]
20. The impact of HBV or HCV infection in a cohort of HIV-infected pregnant women receiving a nevirapine-based antiretroviral regimen in Malawi.
Andreotti M; Pirillo MF; Liotta G; Jere H; Maulidi M; Sagno JB; Luhanga R; Amici R; Mancini MG; Gennaro E; Marazzi MC; Vella S; Giuliano M; Palombi L; Mancinelli S
BMC Infect Dis; 2014 Apr; 14():180. PubMed ID: 24708626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
